PSYCHOTROPIC / PSYCHOACTIVE DRUGS Presented by: Jun Hernandez, R.N. Prepared by: Rhonda Anderson, RHIA.

Slides:



Advertisements
Similar presentations
 QOC related to recognition & management of pain  Determine whether facility has provided & resident has received care & services to address & manage.
Advertisements

Accident Incident Policy Changes to Policy September 2007.
The Basics of Informed Consent: Past, Present & Future DPH RAP Session September 15, 2011 Presented by Elizabeth Plott Tyler TYLER & WILSON 5455 Wilshire.
302 Involuntary Commitment
Health Insurance Portability Accountability Act of 1996 HIPAA for Researchers: IRB Related Issues HSC USC IRB.
HOUSE STAFF ORIENTATION 2013 Charles Conklin Director, Risk Management TUHS John R. O’Donnell, Esquire Senior Counsel TUHS.
{ ADVERSE DRUG REACTIONS To ensure patient, family/caregiver and home health personnel are instructed to identify adverse reactions to medications and.
Medication Regimen Review Guidance Training CFR § (c)(1)(2) F428.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Drug Utilization Review (DUR)
SECLUSION AND RESTRAINT PROVISIONS Marion Greenfield.
DEVELOPING A COMPREHENSIVE CARE PLAN PRESENTED BY LEAH KLUSCH EXECUTIVE DIRECTOR THE ALLIANCE TRAINING CENTER.
Telehealth & Medicare Hospice Conditions of Participation Deborah Randall JD, Attorney/Telehealth Consultant,
Health and Wellness for all Arizonans azdhs.gov Arizona Association for Home Care Presentation Arizona Department of Health Services July 25, 2015.
Hospital Patient Safety Initiatives: Discharge Planning
Medication History: Keeping our patients safe. How do we get all of the correct details?
Palliative Care in the Nursing Home. Objectives Develop an awareness of how a palliative care environment can be created. Recognize the need for changes.
Promoting Excellence in Family Medicine Enabling Patients to Access Electronic Health Records Guidance for Health Professionals.
The Nurse Practice Act.  Defines the Nurse Practice Act and its function  Describes how the Nurse Practice Act applies to the RN Scope of Practice Objectives.
Quality Improvement Prepeared By Dr: Manal Moussa.
1 FACILITY MONITORING October 30, 2008 Presenter: Theresa Gálvez, Chief Patients’ Rights Advocate Riverside County.
Principles of medical ethics Lecture (4) Dr. rawhia Dogham.
The Medical Director F Tag-501Guidance* Kurt Hansen MD, CMD Douglas Englebert RPh September 29, 2005.
1 October, 2005 Activities and Activity Director Guidance Training (F248) §483.15(f)(l), and (F249) §483.15(f)(2)
NORTH AMERICAN HEALTHCARE INFORMED CONSENT. RESIDENT RIGHTS Make decisions Accept or refuse treatment Be free from any physical/chemical restraints Receive.
NORTH AMERICAN HEALTH CARE, INC. DOCUMENTATION–DOCUMENTATION– DOCUMENTATION DOCUMENTATION.
Pharmaceutical Services Guidance Training CFR § , (a)(b)(1) F425.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
# 1: F 282 The services provided or arranged by the facility must be provided by qualified persons in accordance with each resident’s written plan of.
For Pain or Not for Pain: Methadone Madness
Introduction to the new SHC Health Information Record Manual Presented by Rhonda Anderson, RHIA President Anderson Health Information Systems, Inc
Risk Management Preparation - Prevention - Response Janice Sumner, RN VP of Clinical Operations HMRVSI, Inc. July 30, 2015.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
PSYCHOTROPIC / PSYCHOACTIVE DRUGS ARE IN THE HEADLINES PRESENTED BY: LIZETH FLORES, RHIT, RAC-CT ANDERSON HEALTH INFORMATION SYSTEMS, INC. APRIL 16 TH,
HEALTH INFORMATION / RECORD SYSTEMS “Non-Negotiable” Monitoring Systems Process for CQI – Phase I.
Advanced SBAR aka Change of Condition SBAR-Care Paths and Notification to Physicians Brief Note on POSTL Rhonda Anderson, RHIA, President Gayle Edell,
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
NORTH AMERICAN HEALTHCARE PHYSICIAN ORDERS FOR LIFE SUSTAINING TREATMENT (POLST)
HIPAA PRACTICAL APPLICATION WORKSHOP Orientation Module 1B Anderson Health Information Systems, Inc.
Care Management 101 Governor's Office of Health Care Reform October 28, 2010 Cathy Gorski, RN, BS, CCM.
Rhonda Anderson, RHIA, President  …is a PROCESS, not a PROJECT 2.
Landmark Medical Center Licensed Nurse Documentation In-Service March 8, 2010 Presented by Lizeth Flores, RHIT Anderson Health Information Systems, Inc.
Guidance Training CFR §483.75(i) F501 Medical Director.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Guidance Training (F520) §483.75(o) Quality Assessment and Assurance.
Monitoring for Inappropriate Use of Antipsychotic Medications F428 – Drug Regimen Review Process F329 – Unnecessary Medications Margie Huguet, RN, MCS.
Investigational Devices and Humanitarian Use Devices June 2007.
Legal Aspects of Nursing Part 1
Community surgery : staying out of trouble. Miss Nicola Lennard : 12 June 2015:
 Secure resident safety  Assess the resident, provide medical and/or psychosocial treatment as necessary  Examine the resident’s injury and/or psychosocial.
8 Medication Errors and Prevention.
UNITS 4:3-4:4 Patients’ Rights and Legal Directives for Health Care.
PATIENT & FAMILY RIGHTS AT DOHMS. Fully understand and practice all your rights. You will receive a written copy of these rights from the Reception, Registration.
Adult Day Care Chapter 605 Survey Process OSDH. Introduction  Adult Day Care Facilities/Centers are required to be in compliance with laws established.
 Proposed Rule by the Centers for Medicare & Medicaid Services on 11/03/2015Centers for Medicare & Medicaid Services11/03/2015  Revises the discharge.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
Review, Revise and Amend from Procedures for State Board Policy 74
Governing Body QAPI 2013 Update for ASC
The Peer Review Higher Weighted Diagnosis-Related Groups
Non-Compliance Behaviors General Overview of Physical Restraint Requirements for Public Education Programs Prepared by the Massachusetts Department of.
Medical Directors Meeting
Beverley Alberola, CIP Associate Director, Research Protections
Pharmaceutical Care Plan
ADVANCE DIRECTIVES.
The Emergency Medical Treatment and Active Labor Act
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
The Medical Director F Tag-501Guidance*
Optum’s Role in Mycare Ohio
Ethics Committee Guidelines
Presentation transcript:

PSYCHOTROPIC / PSYCHOACTIVE DRUGS Presented by: Jun Hernandez, R.N. Prepared by: Rhonda Anderson, RHIA

PSYCHOTROPIC DRUGS The 2008 Supplemental Guidance highlighted several quality of care areas: Pharmaceutical services – A failure to manage pharmaceutical services properly can seriously jeopardize resident safety and even result in resident deaths. Medication management and psychotropic medications with an emphasis on unnecessary drugs figured prominently. Comprehensive care plans – OIG Supplemental Compliance Program Guidance for Nursing Facilities, Federal Register, Volume 73, No. 190 (September 30, 2008). (

MEDICATION MANAGEMENT Are there medication management processes in place to: Ensure the safe and effective use of medication? Minimize adverse drug interactions and effects? Ensure that irregularities in a resident's drug regimen are promptly discovered and addressed?

MEDICATION MANAGEMENT -2 The key here is to look at the medications and the interactions; not just a statement that the pharmacist and/or Dr. says they were ordered; but the focus is really looking at the interactions, black box warnings; and assessment of the resident by physician and nursing.

PSYCHOTROPIC MEDICATIONS Nursing facilities should ensure that there is an adequate indication for the use of the medication and carefully monitor, document, and review the use of each resident's psychotropic drug. Are the attending physicians, the medical director, the consultant pharmacist, or other care providers within the facility collaborating to evaluate the outcomes of such care? Have you involved family members?

CARE PLANS Are your attending physicians and the consultant pharmacist involved in the development of these care plans? Do your care plans address the medical, nursing, mental and psychosocial needs for each resident? Do they include reasonable objectives and timetables? Do they address medication use – including behavioral indications for use, side effects, boxed warnings (Black Box Warnings)? Are these care plans fully implemented?

POLYPHARMACY… WHAT IS IT? Polypharmacy refers to the concurrent use of multiple medications in a single patient. Traditionally, polypharmacy has a negative connotation. ??? AND REVIEW THE use of multiple medications.

CONCERNS: ANTIPSYCHOTIC POLYPHARMACY The possibility of a higher than necessary numbers of medications; Greater than necessary total dosages and potential for increased short and long-term adverse effects (total side effect burden); Drug-drug interactions; Difficulties in determining the effect of each treatment; Substantially higher costs; A risk for higher morbidity and mortality; and The general lack of evidence for the effectiveness and safety of antipsychotic polypharmacy.

INFORMED CONSENT & PSYCHOTHERAPEUTIC DRUGS "Informed" implies the sharing of information; Similarly, "consent" means agreeing to do something or to allow something to happen. Legal definition of "Informed Consent" at §72052 of CCR, Title 22: Informed consent means the voluntary agreement of a patient, or a representative of an incapacitated patient, to accept a treatment or procedure after receiving information in accordance with Sections 72527(a)(5) and

INFORMED CONSENT -2 This means documentation of the informed consent; either by the physician’s documentation or delegated for a key nursing staff to explain and obtain the written consent when the Dr. is not there – does not mean delegation of the Dr. responsibility. Get the consent when continuing a medication WHEN A RESIDENT IS ADMITTED!

INFORMED CONSENT -3 WHEN A RESIDENT IS ADMITTED FROM AN ACUTE HOSPITAL Obtain a new consent ( after evaluation of the resident – DO NOT discontinue the medication until evaluation and time to titrate the medication – get informed consent and go from there based on the needs of the resident). The physicians is not there – the facility designee must get the consent.

OBTAIN INFORMED CONSENT Try to obtain the consent of the resident to notify the resident’s interested family member, as designated in the medical record. If the resident consents to the notice, the physician shall make reasonable attempts, either personally or through a designee, to notify the interested family member, as designated in the medical record.

ALL FACILITY LETTER INFORMED CONSENT Purpose of this letter was to notify all SNFs of a change in guidance at CCR, Title 22, Section 72528(c) Before initiating the administration of psychotherapeutic drugs, or physical restraints, facility staff shall verify that the patient's health record contains documentation that the patient has given informed consent to the proposed treatment or procedure. The facility shall also ensure that all decisions concerning the withdrawal or withholding of life sustaining treatment are documented in the patient's health record.

INFORMED CONSENT -4 For the prolonged use of a device that may lead to the inability to regain use of a normal bodily function – also requires informed consent and risk/benefits provided and documentation in the record.

DPH L & C Informed consent must be obtained even when resident is admitted from an acute hospital with the preexisting orders for psychotherapeutic drugs, or physical restraints, or the prolonged use of a device that may lead to the inability to regain use of a normal bodily function. SNF MUST VERIFY informed consent and assure documentation in the patient’s medical record.

DPH L & C -2 Section 72528(c). The Department has determined that in order to verify compliance with Section 72528(c), surveyors must confirm that health records contain documentation that the patient gave informed consent for the treatments listed in the regulation for all residents, including those admitted with preexisting orders.

DPH L & C -3 Therefore, effective immediately, all SNF shall verify that the patient’s health record contains documentation that the patient has given informed consent to the proposed treatment or procedure as written in Section 72528(c).

DPH L & C -4 In order for SNF to be in full compliance with this regulation, the Department suggests a few methods that are permitted under current regulations and/or statutes. Obtain documentation that informed consent had been obtained from the patient for the proposed therapy and that it is in the patient’s clinical record. Obtain new informed consent as described in Section 72528(c) and place the informed consent documentation in the patient’s medical record. FL.aspx FL.aspx

WHAT TO DO NOW… At time of admission; when admission orders are obtained – obtain a signed consent from the appropriate person (resident if has the capacity to give consent); (same as signing admission consents; resident should sign). Contact physician to be sure the Physician wants medication continued, of course.

WHAT TO DO NOW… -2 Nursing staff will need to provide the informed consent to the resident (physician is not available); this does not delegate the Drs. Accountability for informed consent. All new psychotherapeutic drugs, either physician or delegated nursing staff must obtain informed consent. Recommend Dr. review with resident on next admission and sign the informed consent.

WHAT TO DO NOW… -3 Take all the resident’s psychotherapeutic medications and determine if you have a consent now (even for those residents admitted without a consent and one was not received ever in the facility). Obtain a new informed consent; recommend initiate ASAP and the physician review and discuss with resident and sign informed consent on next visit indicating review with the resident or designated or legal representative.

WHAT TO DO NOW… -4 Identify all residents with catheters or other devices that may be used that would alter the resident’s body function – identify those and obtain written consent to continue their use – same as with on admission. Either a form or have available the risks and benefits of devices available so nurses know what to say if ???

WHAT TO DO NOW… -5 Inform all nursing staff admitting residents about the need to get an informed consent and what that is meant in this new focus on consents on admission for INFORMED CONSENT.

POLICIES & PROCEDURES Administrative and Medical Record Manuals will be updated and provided to the facility. Administrative #4030 on consents; HIM/Record Manual – Admission audit, psychoactive drug audit and will add these and devices to Change of Condition reviews; Consents #5025 – Antipsychotic Consent/Notification, page 4; Other related policies and audits.

REGULATION REFERENCES SUPPORT FOR UPDATING POLICIES AND PROCEDURES for informed consent, psychotherapeutic / psychotropic / psychoactive drugs and regulatory grouping: CCR, Title 22, Division 5, Chapter 3 Skilled Nursing Facilities – §72319 Nursing Service—Restraints and Postural Supports – §72527 Patients’ Rights – §72528 Informed Consent Requirements

REGULATION REFERENCES -2 Regulations (continued): H&SC (a.k.a. the Epple Act) (focus on antipsychotic use), and (devolution of rights) 42 CFR State Operations Manual, Appendix PP F152 §483.10(a)(3) and (4) Rights of incompetent; rights designated to a surrogate; F154 §483.10(b)(3) Right to be fully informed; F155 §483.10(b)(4) Right to refuse treatment F222 §483.13(a) Restraints (chemical) F329 §483.25(l) Unnecessary Drugs F428 §483.60(c) Drug Regimen Review

THANK YOU FOR ATTENDING!